Form 4: SpringWorks Therapeutics CEO Reports Full Disposal of Equity Holdings Post-Merger with Merck KGaA

SpringWorks Therapeutics, Inc. CEO Saqib Islam reported the disposal of all his beneficial ownership in company common stock, restricted stock units, performance share units, and stock options effective July 1, 2025, as a result of the company's merger with Merck KGaA.

Summary

• The filing reports the disposal of all beneficial ownership by Saqib Islam, CEO of SpringWorks Therapeutics, Inc. (SWTX), in common stock, restricted stock units (RSUs), performance share units (PSUs), and stock options.
• The disposals occurred on July 1, 2025, as a direct result of the merger between SpringWorks Therapeutics, Inc. and Merck KGaA, Darmstadt, Germany, through its subsidiary EMD Holdings Merger Sub, Inc.
• Under the terms of the Merger Agreement, dated April 27, 2025, SpringWorks Therapeutics became a wholly-owned subsidiary of Merck KGaA.
• Each outstanding share of SpringWorks Therapeutics common stock was cancelled and converted into the right to receive $47.00 in cash per share.
• Outstanding RSUs, whether vested or unvested, were cancelled and converted into cash amounts based on the $47.00 merger consideration, becoming 'Parent Cash-Based RSU Awards' that generally vest according to original terms, with 50% of unvested tranches vesting on the nine-month anniversary of the closing date, subject to continued employment.
• Outstanding PSUs, whether vested or unvested, were cancelled and converted into cash amounts based on the $47.00 merger consideration and the achievement of performance levels.
• Vested and unvested stock options were cancelled and converted into cash amounts equal to the product of the number of shares and the excess of the $47.00 merger consideration over the option's exercise price. Unvested options became 'Parent Cash-Based Option Awards' with similar vesting terms to RSUs.
• Any outstanding stock options with an exercise price greater than $47.00 were cancelled for no consideration.
• Saqib Islam disposed of 954,869 shares of Common Stock (including 162,414 shares underlying RSUs), 579,749 Performance Share Units, and a total of 1,913,304 Stock Options with various exercise prices ranging from $1.65 to $43.00.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger, resulting in a cash payout for shareholders and equity holders, which is generally a positive outcome for those holding the stock. However, it's a factual report of a past event, not a new positive development.

Positives

• The completion of the merger provides a definitive cash payout of $47.00 per share to SpringWorks Therapeutics shareholders.
• Equity award holders, including the CEO, received cash consideration for their holdings, with unvested awards converting to cash-based awards that continue to vest, providing retention incentives for key personnel under the new ownership.

Negatives

• SpringWorks Therapeutics, Inc. ceased to be an independent publicly traded company.
• Stock options with an exercise price greater than the $47.00 merger consideration were cancelled for no value.

Future Outlook

SpringWorks Therapeutics, Inc. is now a wholly-owned subsidiary of Merck KGaA. Certain unvested equity awards held by employees, including the CEO, have been converted into cash-based awards that will continue to vest based on original terms and continued employment, with a specific vesting acceleration on the nine-month anniversary of the merger closing date.

Industry Context

This filing reflects the finalization of a significant acquisition in the biopharmaceutical sector, a common trend where larger pharmaceutical companies acquire smaller, innovative biotech firms to expand their pipelines and therapeutic areas. Merck KGaA's acquisition of SpringWorks Therapeutics aligns with strategic growth through M&A.

Comparison to Industry Standards

• The transaction structure, involving a cash-out merger and conversion of equity awards, is standard for acquisitions in the biopharmaceutical industry.
• The treatment of out-of-the-money options being cancelled for no consideration is also a common practice in such transactions.

Corporate Governance

Stakeholder Impact

• Shareholders: Received a cash payment of $47.00 per share for their common stock.
• Employees (including the CEO): Equity awards were converted into cash-based awards, with continued vesting tied to employment, providing a retention mechanism under the new ownership.

Next Steps

• Continued vesting of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards, with 50% of each then-unvested tranche vesting on the nine-month anniversary of the merger closing date, subject to continued employment.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger, Acquisition, Form 4, Beneficial Ownership, Equity Awards, Stock Options, Restricted Stock Units, Performance Share Units, Saqib Islam, Biopharmaceutical